Gosset C2N Diagnostics General Information
The company's flagship blood tests, including PrecivityAD® and PrecivityAD2™, have demonstrated clinical diagnostic performance comparable to gold-standard amyloid PET imaging and CSF biomarkers. These tests are available in the US and select international markets, with over fifteen thousand biomarker measures reported in peer-reviewed publications. Their technology has been used in major clinical trials—including those supporting new Alzheimer’s therapies—and continues to expand globally through partnerships.[3][4][10]
Contact Information
USA
Drug Pipeline
Key Partnerships
Eisai Inc./Co., Ltd. – investment and use of assays in LEQEMBI® clinical trials for Alzheimer's therapy support[3][10]., Unilabs – multi-year exclusive partnership to distribute Precivity™ portfolio across Europe, Peru, Saudi Arabia, UAE.[7], National Institute on Aging/National Institutes of Health – research funding/collaboration support [4]., Alzheimer's Drug Discovery Foundation – significant funding via Diagnostics Accelerator initiative [7].
C2N Diagnostics Funding
| Deal Type | Date | Amount | Status | Stage |
|---|---|---|---|---|
| Investment | Mar 12, 2026 | $10.0M | Completed | Commercial |